New balloon ablation could change early AFib treatment

NCT ID NCT07621003

Not yet recruiting Disease control Sponsor: Asklepios proresearch Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This study tests a procedure called pulsed field ablation (PFA) for people with early-stage atrial fibrillation (AFib) diagnosed within the last 3 years. The procedure uses a balloon to deliver energy that isolates the pulmonary veins, aiming to stop abnormal heart rhythms. Researchers will compare PFA to usual care (medication) in 264 adults over 12 months to see if it reduces AFib episodes and hospitalizations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pulsed field ablation (a procedure using a balloon to deliver energy to isolate pulmonary veins)
What this could lead to: If successful, this could offer a more effective first-line treatment for early atrial fibrillation, potentially reducing the need for long-term medication.
What could go wrong: This is an early-stage study with 264 participants, so results may not apply to all patients. The procedure carries risks like bleeding, heart damage, or arrhythmia recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation paroxysmal atrial fibrillation persistent atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION

Contacts and locations

Locations

Arian Sultam

Hamburg, 20099, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.